BACKGROUND: Recent findings indicate that inhibitors of fatty acid amide hydrolase (FAAH) counteract the rewarding effects of nicotine in rats. Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoid anandamide and the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-α). Here, we evaluated whether directly acting PPAR-α agonists can modulate reward-related effects of nicotine. METHODS: We combined behavioral, neurochemical, and electrophysiological approaches to evaluate effects of the PPAR-α agonists [[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid (WY14643) and methyl oleoylethanolamide (methOEA; a long-lasting form of OEA) on 1) nicotine self-administration in rats and squirrel monkeys; 2) reinstatement of nicotine-seeking behavior in rats and monkeys; 3) nicotine discrimination in rats; 4) nicotine-induced electrophysiological activity of ventral tegmental area dopamine neurons in anesthetized rats; and 5) nicotine-induced elevation of dopamine levels in the nucleus accumbens shell of freely moving rats. RESULTS: The PPAR-α agonists dose-dependently decreased nicotine self-administration and nicotine-induced reinstatement in rats and monkeys but did not alter food- or cocaine-reinforced operant behavior or the interoceptive effects of nicotine. The PPAR-α agonists also dose-dependently decreased nicotine-induced excitation of dopamine neurons in the ventral tegmental area and nicotine-induced elevations of dopamine levels in the nucleus accumbens shell of rats. The ability of WY14643 and methOEA to counteract the behavioral, electrophysiological, and neurochemical effects of nicotine was reversed by the PPAR-α antagonist 1-[(4-Chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-a,a-dimethyl-5-(1-methylethyl)-1H-Indole-2-propanoic acid (MK886). CONCLUSIONS: These findings indicate that PPAR-α might provide a valuable new target for antismoking medications. Published by Elsevier Inc.
BACKGROUND: Recent findings indicate that inhibitors of fatty acid amide hydrolase (FAAH) counteract the rewarding effects of nicotine in rats. Inhibition of FAAH increases levels of several endogenous substances in the brain, including the endocannabinoidanandamide and the noncannabinoid fatty acidethanolamidesoleoylethanolamide (OEA) and palmitoylethanolamide, which are ligands for alpha-type peroxisome proliferator-activated nuclear receptors (PPAR-α). Here, we evaluated whether directly acting PPAR-α agonists can modulate reward-related effects of nicotine. METHODS: We combined behavioral, neurochemical, and electrophysiological approaches to evaluate effects of the PPAR-α agonists [[4-Chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid (WY14643) and methyl oleoylethanolamide (methOEA; a long-lasting form of OEA) on 1) nicotine self-administration in rats and squirrel monkeys; 2) reinstatement of nicotine-seeking behavior in rats and monkeys; 3) nicotine discrimination in rats; 4) nicotine-induced electrophysiological activity of ventral tegmental area dopamine neurons in anesthetized rats; and 5) nicotine-induced elevation of dopamine levels in the nucleus accumbens shell of freely moving rats. RESULTS: The PPAR-α agonists dose-dependently decreased nicotine self-administration and nicotine-induced reinstatement in rats and monkeys but did not alter food- or cocaine-reinforced operant behavior or the interoceptive effects of nicotine. The PPAR-α agonists also dose-dependently decreased nicotine-induced excitation of dopamine neurons in the ventral tegmental area and nicotine-induced elevations of dopamine levels in the nucleus accumbens shell of rats. The ability of WY14643 and methOEA to counteract the behavioral, electrophysiological, and neurochemical effects of nicotine was reversed by the PPAR-α antagonist 1-[(4-Chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-a,a-dimethyl-5-(1-methylethyl)-1H-Indole-2-propanoic acid (MK886). CONCLUSIONS: These findings indicate that PPAR-α might provide a valuable new target for antismoking medications. Published by Elsevier Inc.
Authors: Jin Fu; Silvana Gaetani; Fariba Oveisi; Jesse Lo Verme; Antonia Serrano; Fernando Rodríguez De Fonseca; Anja Rosengarth; Hartmut Luecke; Barbara Di Giacomo; Giorgio Tarzia; Daniele Piomelli Journal: Nature Date: 2003-09-04 Impact factor: 49.962
Authors: Bernard Le Foll; Svetlana I Chefer; Alane S Kimes; Elliot A Stein; Steven R Goldberg; Alexey G Mukhin Journal: Psychopharmacology (Berl) Date: 2016-02-25 Impact factor: 4.530
Authors: Francisco J Pavon; Antonia Serrano; Nimish Sidhpura; Ilham Polis; David Stouffer; Fernando Rodriguez de Fonseca; Benjamin F Cravatt; Rémi Martin-Fardon; Loren H Parsons Journal: Addict Biol Date: 2017-06-29 Impact factor: 4.280
Authors: Ainhoa Bilbao; Antonia Serrano; Andrea Cippitelli; Francisco J Pavón; Andrea Giuffrida; Juan Suárez; Nuria García-Marchena; Elena Baixeras; Raquel Gómez de Heras; Laura Orio; Francisco Alén; Roberto Ciccocioppo; Benjamin F Cravatt; Loren H Parsons; Daniele Piomelli; Fernando Rodríguez de Fonseca Journal: Addict Biol Date: 2015-06-02 Impact factor: 4.280
Authors: Esmaeil Mansouri; José N Nobrega; Matthew N Hill; Rachel F Tyndale; Francis S Lee; Christian S Hendershot; Laura M Best; Patricia Di Ciano; Georgia Balsevich; Mathew E Sloan; Stephen J Kish; Junchao Tong; Bernard Le Foll; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2019-11-27 Impact factor: 7.853
Authors: Islam Gamaleddin; Mihail Guranda; Maria Scherma; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Steven R Goldberg; Bernard Le Foll Journal: J Psychopharmacol Date: 2013-02-20 Impact factor: 4.153